64 related articles for article (PubMed ID: 28971496)
1. PSCA promotes prostate cancer proliferation and cell-cycle progression by up-regulating c-Myc.
Li E; Liu L; Li F; Luo L; Zhao S; Wang J; Kang R; Luo J; Zhao Z
Prostate; 2017 Dec; 77(16):1563-1572. PubMed ID: 28971496
[TBL] [Abstract][Full Text] [Related]
2. GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy.
Mukha A; Kahya U; Linge A; Chen O; Löck S; Lukiyanchuk V; Richter S; Alves TC; Peitzsch M; Telychko V; Skvortsov S; Negro G; Aschenbrenner B; Skvortsova II; Mirtschink P; Lohaus F; Hölscher T; Neubauer H; Rivandi M; Labitzky V; Lange T; Franken A; Behrens B; Stoecklein NH; Toma M; Sommer U; Zschaeck S; Rehm M; Eisenhofer G; Schwager C; Abdollahi A; Groeben C; Kunz-Schughart LA; Baretton GB; Baumann M; Krause M; Peitzsch C; Dubrovska A
Theranostics; 2021; 11(16):7844-7868. PubMed ID: 34335968
[TBL] [Abstract][Full Text] [Related]
3. NCAPG2 promotes prostate cancer malignancy and stemness via STAT3/c-MYC signaling.
Zhang E; Chen Z; Liu W; Lin L; Wu L; Guan J; Wang J; Kong C; Bi J; Zhang M
J Transl Med; 2024 Jan; 22(1):12. PubMed ID: 38166947
[TBL] [Abstract][Full Text] [Related]
4. Essential role of JunD in cell proliferation is mediated via MYC signaling in prostate cancer cells.
Elliott B; Millena AC; Matyunina L; Zhang M; Zou J; Wang G; Zhang Q; Bowen N; Eaton V; Webb G; Thompson S; McDonald J; Khan S
Cancer Lett; 2019 Apr; 448():155-167. PubMed ID: 30763715
[TBL] [Abstract][Full Text] [Related]
5. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer.
Reiter RE; Gu Z; Watabe T; Thomas G; Szigeti K; Davis E; Wahl M; Nisitani S; Yamashiro J; Le Beau MM; Loda M; Witte ON
Proc Natl Acad Sci U S A; 1998 Feb; 95(4):1735-40. PubMed ID: 9465086
[TBL] [Abstract][Full Text] [Related]
6. Exportin XPO7 acts as an oncogenic factor in prostate cancer via upregulation of TCF3.
Lin Y; Zhan M; Xu B
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7663-7677. PubMed ID: 37000263
[TBL] [Abstract][Full Text] [Related]
7. Receptor-interacting protein kinase 2 (RIPK2) stabilizes c-Myc and is a therapeutic target in prostate cancer metastasis.
Yan Y; Zhou B; Qian C; Vasquez A; Kamra M; Chatterjee A; Lee YJ; Yuan X; Ellis L; Di Vizio D; Posadas EM; Kyprianou N; Knudsen BS; Shah K; Murali R; Gertych A; You S; Freeman MR; Yang W
Nat Commun; 2022 Feb; 13(1):669. PubMed ID: 35115556
[TBL] [Abstract][Full Text] [Related]
8. ANP32B inhibition suppresses the growth of prostate cancer cells by regulating c-Myc signaling.
Zhou C; Ma H; Yu W; Zhou Y; Zhang X; Meng Y; Chen C; Zhang J; Shi G
Biochem Biophys Res Commun; 2024 Feb; 698():149543. PubMed ID: 38266312
[TBL] [Abstract][Full Text] [Related]
9. A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer.
Morris MJ; Eisenberger MA; Pili R; Denmeade SR; Rathkopf D; Slovin SF; Farrelly J; Chudow JJ; Vincent M; Scher HI; Carducci MA
Ann Oncol; 2012 Oct; 23(10):2714-2719. PubMed ID: 22553195
[TBL] [Abstract][Full Text] [Related]
10. The Oncogenic Protein Kinase/ATPase RIOK1 Is Up-Regulated via the c-myc/E2F Transcription Factor Axis in Prostate Cancer.
Handle F; Puhr M; Gruber M; Andolfi C; Schäfer G; Klocker H; Haybaeck J; De Wulf P; Culig Z
Am J Pathol; 2023 Sep; 193(9):1284-1297. PubMed ID: 37301535
[TBL] [Abstract][Full Text] [Related]
11. Anillin contributes to prostate cancer progression through the regulation of IGF2BP1 to promote c-Myc and MAPK signaling.
Liu J; Wang S; Zhang C; Wei Z; Han D; Song Y; Song X; Chao F; Wu Z; Xu G; Chen G
Am J Cancer Res; 2024; 14(2):490-506. PubMed ID: 38455417
[TBL] [Abstract][Full Text] [Related]
12. ADP-dependent glucokinase controls metabolic fitness in prostate cancer progression.
Xu H; Li YF; Yi XY; Zheng XN; Yang Y; Wang Y; Liao DZ; Zhang JP; Tan P; Xiong XY; Jin X; Gong LN; Qiu S; Cao DH; Li H; Wei Q; Yang L; Ai JZ
Mil Med Res; 2023 Dec; 10(1):64. PubMed ID: 38082365
[TBL] [Abstract][Full Text] [Related]
13. Nucleophosmin 1 cooperates with BRD4 to facilitate c-Myc transcription to promote prostate cancer progression.
Hong Z; Xu C; Zheng S; Wang X; Tao Y; Tan Y; Lin G; Wu D; Ye D
Cell Death Discov; 2023 Oct; 9(1):392. PubMed ID: 37875480
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the Gene Networks and Pathways Correlated with Tissue Differentiation in Prostate Cancer.
Filippi A; Aurelian J; Mocanu MM
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612439
[TBL] [Abstract][Full Text] [Related]
15. OTUB1 Promotes Progression and Proliferation of Prostate Cancer via Deubiquitinating and Stabling Cyclin E1.
Liao Y; Wu N; Wang K; Wang M; Wang Y; Gao J; Zhong B; Ma F; Wu Y; Jiang N
Front Cell Dev Biol; 2020; 8():617758. PubMed ID: 33537306
[No Abstract] [Full Text] [Related]
16. Antitumor activity of genetically engineered NK-cells in non-hematological solid tumor: a comprehensive review.
Dash CP; Sonowal D; Dhaka P; Yadav R; Chettri D; Satapathy BP; Sheoran P; Uttam V; Jain M; Jain A
Front Immunol; 2024; 15():1390498. PubMed ID: 38694508
[TBL] [Abstract][Full Text] [Related]
17. Unveiling the potential of SLURP1 protein as a biomarker for prostate cancer screening.
Yang T; Liu T; Lei T; Li T; Liu N; Zhang M
Front Oncol; 2024; 14():1365615. PubMed ID: 38686195
[TBL] [Abstract][Full Text] [Related]
18. Significance of PSCA as a novel prognostic marker and therapeutic target for cancer.
Nayerpour Dizaj T; Doustmihan A; Sadeghzadeh Oskouei B; Akbari M; Jaymand M; Mazloomi M; Jahanban-Esfahlan R
Cancer Cell Int; 2024 Apr; 24(1):135. PubMed ID: 38627732
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor-modified T cells therapy in prostate cancer: A comprehensive review on the current state and prospects.
He M; Zhang D; Cao Y; Chi C; Zeng Z; Yang X; Yang G; Sharma K; Hu K; Enikeev M
Heliyon; 2023 Aug; 9(8):e19147. PubMed ID: 37664750
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
